PX107 protein vaccine induces an antibody response toward a protein that is increased or imbalanced in diseases such as osteoporosis and rheumatoid arthritis.
Cobra Biomanufacturing will manufacture Pharmexa’s PX107 protein vaccine for use in Phase I trials for bone disorders. The program will include cell banking, process development, and GMP manufacture.
The vaccine makes use of Pharmexa’s active immunotherapy technology, AutoVac™. The company reports that PX107 induces a polyclonal antibody response toward the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis, and bone metastasis with pathological bone destruction.
Pharmexa will be carrying out the upstream and downstream development of PX107 but requires Cobra’s cGMP manufacturing capabilities to produce the material for Phase I trials, explains David Thatcher, chief executive of Cobra Biomanufacturing.